Your browser doesn't support javascript.
loading
Antihistamines and Ovarian Cancer Survival: Nationwide Cohort Study and in Vitro Cell Viability Assay.
Verdoodt, Freija; Dehlendorff, Christian; Jäättelä, Marja; Strauss, Robert; Pottegård, Anton; Hallas, Jesper; Friis, Søren; Kjaer, Susanne K.
Afiliación
  • Verdoodt F; Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Centre, Copenhagen, Denmark.
  • Dehlendorff C; Belgian Cancer Registry, Brussels, Belgium.
  • Jäättelä M; Unit of Statistics and Pharmacoepidemiology, Danish Cancer Society Research Centre, Copenhagen, Denmark.
  • Strauss R; Cell Death & Metabolism, Centre for Autophagy, Recycling and Disease, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Pottegård A; Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Hallas J; Genome Integrity Unit, Danish Cancer Society Research Centre, Copenhagen, Denmark.
  • Friis S; Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Kjaer SK; Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
J Natl Cancer Inst ; 112(9): 964-967, 2020 09 01.
Article en En | MEDLINE | ID: mdl-31688928
Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between filled antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a hazard ratio of 0.63 (95% CI = 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendency toward a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Tensoactivos / Carcinoma Epitelial de Ovario / Antagonistas de los Receptores Histamínicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Natl Cancer Inst Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Tensoactivos / Carcinoma Epitelial de Ovario / Antagonistas de los Receptores Histamínicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Natl Cancer Inst Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Estados Unidos